ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 1771 • ACR Convergence 2022

    The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

    Yanjie Hao1, Shereen Oon2 and Mandana Nikpour3, 1The University of Melbourne, Melbourne, Australia, 2The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, 3The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…
  • Abstract Number: 2122 • ACR Convergence 2022

    Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

    Dafna Gladman1, Lars Erik2, Diamant Thaci3, Paolo Gisondi4, Laure Gossec5, M. Elaine Husni6, Alice Gottlieb7, Hiroaki Dobashi8, Barbara Ink9, Deepak Assudani9, Rajan Bajracharya9, Jason Coarse10, Jérémy Lambert11 and William Tillett12, 1Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 2Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 3Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, 4Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, 5Sorbonne Université, Paris, France, 6Cleveland Clinic, Cleveland, OH, 7Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, 8Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 11UCB Pharma, Colombes, France, Irigny, France, 12Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: PsA imparts a substantial burden on patient health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition…
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • Abstract Number: 2205 • ACR Convergence 2022

    Non-Invasive in Vivo Metabolic Profiling of Inflammation in Joints and Entheses by Optoacoustic Imaging

    Koray Tascilar1, Filippo Fagni2, Arnd Kleyer1, Sara Bayat2, Robert Heidemann3, Florian Steiger3, Gerhard Kroenke1, Daniela Bohr4, Andreas Ramming1, Melek Yalcin Mutlu3, Ioanna Minopoulou3, Fabian Hartmann3, Daniel Klett5, Anna Federle5, Adrian Regensburger6, Alexandra L. Wagner6, Ferdinand Knieling6, Markus Neurath5, Georg Schett7, Maximilian Waldner5 and David Simon1, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 3University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 4Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, 5University Hospital Erlangen; Department of Internal Medicine 1 - Gastroenterology, Pulmonology and Immunology, Erlangen, Germany, 6University Hospital Erlangen; Department of Pediatrics and Adolescent Medicine, Erlangen, Germany, 7Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: For individuals with inflammatory arthritis, a detailed metabolic characterization of joints and entheses at the tissue level can aid in early diagnosis and treatment…
  • Abstract Number: 0088 • ACR Convergence 2022

    Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review

    Andre Ribeiro1, Larissa Dullius2, Andre Azeredo2, Laura Coates3, Odirlei Monticielo2, Charles Kohem2, Penelope Palominos2 and Natalia Sartori1, 1Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 2Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: In 2020, the International League of Associations for Rheumatology (ILAR) recommendations for management of psoriatic arthritis (PsA) were published. It aimed to adapt GRAPPA…
  • Abstract Number: 0391 • ACR Convergence 2022

    Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data

    William Tillett1, Alexander Egeberg2, Enikö Sonkoly3, Patricia Gorecki4, Anna Tjärnlund5, Jozefien Buyze6, Sven Wegner7 and Dennis McGonagle8, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, 3Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 4Janssen-Cilag Ltd, High Wycombe, United Kingdom, 5Janssen-Cilag AB, Solna, Sweden, 6Janssen Pharmaceutica NV, Beerse, Belgium, 7Janssen-Cilag GmbH, Neuss, Germany, 8Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed…
  • Abstract Number: 0807 • ACR Convergence 2022

    High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients

    Viviana Marzaioli1, Achilleas Floudas2, Aine Gorman3, Carl Orr4, Douglas Veale5 and Ursula Fearon6, 1Trinity College Dublin and University College Dublin, Dublin, Ireland, 2Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, 3St Vincent's University Hospital, Dublin, Ireland, 4Saint Vincent's University Hospital, Dublin, Ireland, 5St. Vincent's University Hospital, Blackrock, Dublin, Ireland, 6Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Inflammatory arthritis (IA) is a chronic systemic autoimmune disease of unknown aetiology, which affects the joints. While studies of immune cell populations in peripheral…
  • Abstract Number: 1028 • ACR Convergence 2022

    How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?

    Conor Coyle1, Caroline Whately-Smith2, Melanie Brooke3, Uta Kiltz4, Ennio Lubrano5, Ruben Queiro6, David Trigos7, Jan Brandt-Juergens8, Salvatore D'Angelo9, Andrea Delle Sedie10, Emmanuelle Dernis11, Philip Helliwell12, Pauline Ho13, Axel Hueber14, BEATRIZ E. JOVEN15, Michaela Koehm16, Carlos Montilla17, Jon Packham18, JOSE PINTO TASENDE19, Felipe Julio Ramirez Garcia20, Adeline Ruyssen-Witrand21, Rossana Scrivo22, sarah twigg23, Martin Welcker24, Theo Wirth25, Laure Gossec26 and Laura Coates27, 1Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 2Whately-Smith Ltd, Kings Langley, United Kingdom, 3Bath Institute for Rheumatic Disease, Bath, United Kingdom, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, 6Faculty of Medicine, Rheumatology Service & the Principality of Asturias Institute for Health Research (ISPA), Universidad de Oviedo, Oveido, Spain, 7Patient partner, Oveido, Spain, 8Rheumatologische Schwerpunktpraxis, Berlin, Germany, 9Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, 10University of Pisa, Pisa, Pisa, Italy, 11LE MANS general hospital, LE MANS, France, 12Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 13The Kellgren Centre for Rheumatology, Manchester, United Kingdom, 14Paracelsus University Nürnberg, Erlangen, Germany, 15Hospital Universitario 12 de Octubre, Madrid, Spain, 16Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, 17Complejo asistencial Universitario de Salamanca, Salamanca, Spain, 18University of Nottingham, Stafford, United Kingdom, 19SERGAS, A Coruña, Spain, 20Hospital Clínic, Barcelona, Spain, 21CHU de Toulouse, Toulouse, France, 22Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, 23Bradford Teaching hospitals NHS foundation trust, Bradford, United Kingdom, 24GBR, Planegg, Germany, 25Aix Marseille University, Marseille, France, 26Sorbonne Université, Paris, France, 27Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous, multi-dimensional disease. Little is known about factors underpinning treatment intensification in routine practice. Treatment pathways are not well…
  • Abstract Number: 1161 • ACR Convergence 2022

    IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

    Marie-Christin Hoffmann1, Natalie Fadle1, Evi Regitz1, Klaus-Dieter Preuss1, Marina Zaks2, Elisabeth Stöger3, Vincent Zimmer4, Philipp Klemm5, Gunter Assmann6, Bernhard Thurner7, Claudia Pföhler8, Joerg Thomas Bittenbring1, Christoph Kessel9 and Lorenz Thurner1, 1José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, 2Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, 3Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, 4Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, 5Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, 6Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, 7Department of Pediatrics, Klinikum Kempten, Kempten, Germany, 8Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, 9Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany

    Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
  • Abstract Number: 1486 • ACR Convergence 2022

    Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis

    Keith Colaco1, Ker-Ai Lee2, Vinod Chandran3, Paula Harvey4, Richard Cook2, Vincent Piguet4, Dafna Gladman5 and Lihi Eder6, 1University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Women's College Hospital, Toronto, ON, Canada, 5Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 6Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Cardiovascular risk in patients with psoriatic disease (PsD) may be underestimated by conventional scoring systems. We derived and internally validated a 5-year disease-specific cardiovascular…
  • Abstract Number: 1509 • ACR Convergence 2022

    Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations

    Xenofon Baraliakos1, Effie Pournara2, Dafna Gladman3, Philip J Mease4, Samad S Jahandideh2 and Laura Coates5, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 4Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Universally acceptable clinical and imaging criteria to define axial psoriatic arthritis (PsA) is lacking.1 Machine learning (ML) algorithms can detect patterns from large clinical…
  • Abstract Number: 1850 • ACR Convergence 2022

    Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

    Jeffrey Curtis1, Iain B McInnes2, Proton Rahman3, Dafna Gladman4, Feifei Yang5, Steve Peterson5, Alexa Kollmeier6, Natalie Shiff7, Chenglong Han8, May Shawi9, William Tillett10 and Philip J Mease11, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 3Memorial University, St. John's, NL, Canada, 4Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 5Department of Immunology, Janssen Global Services, LLC, Horsham, PA, 6Janssen-Cilag, Research & Development, LLC, San Diego, CA, 7Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, 8Immunology, Janssen Research & Development, LLC, Spring House, PA, 9Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 10Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 11Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Psoriatic arthritis (PsA), a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis, and skin/nail psoriasis, is associated with reduced health-related quality…
  • Abstract Number: 2123 • ACR Convergence 2022

    Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis

    Jesus Diaz1, Guillermo Quiceno2 and Adela Castro3, 1Hamilton Medical Center, Chattanooga, TN, 2UT Southwestern Medical Center, Dallas, TX, 3Hamilton Physician Group-Specialty Care, Dalton, GA

    Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly…
  • Abstract Number: 2140 • ACR Convergence 2022

    Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast

    Philip J Mease1, Dafna Gladman2, Georg Schett3, Maria Paris4, Sue Cheng5, Sven Richter5, Lichen Teng5 and Arthur Kavanaugh6, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Universitätsklinikum Erlangen, Erlangen, Germany, 4Amgen Inc., Westfield, NJ, 5Amgen, Inc., Thousand Oaks, CA, 6University of California San Diego, La Jolla, CA

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic systemic inflammatory musculoskeletal disease. The potential relationship between PsA therapies and specific safety events such as major adverse…
  • Abstract Number: 2206 • ACR Convergence 2022

    Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

    Lihi Eder1, Fangya Ma2, Josefina Marin3, Minna Kohler4, Janeth Yinh5, Ari Polachek6, Marcos Rosemffet7, Ernesto Rodriguez8, Ilaria Tinnazzi9, Amir Haddad10, Philippe Carron11, Mariana Alves Ferreira Martins12, Catherine Bakewell13, Fahmeen J. Afgani14, Richard Cook2, Sibel Aydin15 and Gurjit S. Kaeley16, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Boston, MA, 6Tel Aviv Medical Center, Tel Aviv, Israel, 7Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 8Florida Medical Clinic, Tampa, FL, 9Ospedale Sacro Cuore-Don Calabria, Negrar, Italy, 10Carmel Medical Centre, Haifa, Israel, 11Ghent University Hospital, Ghent, Belgium, 12São José Do Rio Preto Medical School, São José do Rio Preto, Brazil, 13Intermountain Healthcare, Salt Lake City, UT, 14Women's College Hospital, Toronto, ON, Canada, 15University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, 16UF COM-J, Ponte Vedra Beach, FL

    Background/Purpose: Variability in scoring of sonographic entheseal lesions may be influenced by patient characteristics and sonographer expertise. We aimed to assess inter-rater agreement in scoring…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 60
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences